Clinical trial

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

NCT03446547

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-12-04

PhasePHASE2

Study timeline

Study start (actual)2017-12-04Date precision: day

Registry last updated2026-04-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLC, Stage Iunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Vastra Gotaland Regionlead sponsor

AstraZenecacollaborator

Mapped research locations

StockholmSweden1 GothenburgSweden1 OsloNorway1 HelsinkiFinland1 LundSweden1 TurkuFinland1 TampereFinland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03446547 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.